Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 3, 2023Journal of Thrombosis and HaemostasisOpen Access

Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII

View Full Paper
Ask AI
Bookmark
Share

Authors

AHAndreas HillarpLund UniversityPHPål André HolmeOslo University HospitalEWErik Pareli WålandOslo University Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hillarp et al. (2023) studied this question.

synapsesocial.com/papers/6a849fe212e994284115a962https://doi.org/10.1016/j.jtha.2023.07.019
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A2015 · 263 citations
  2. 2Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study2021 · 21 citations
  3. 3The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability1995 · 659 citations
  4. 4Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study2022 · 11 citations
  5. 5Long‐term safety and efficacy of N8‐GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder22020 · 28 citations